Newsroom - Page 7

Zarxio (filgrastim-sndz), manufactured by Sandoz as a biosimilar to Amgen's Neupogen, has finally received marketing approval from a federal appeals court.
More than half of patients in numerous disease states are nonadherent to their medications and 30% of patients do not fill their prescriptions.
Merck (MSD) has announced that its PD-1 inhibitor pembrolizumab (Keytruda) was approved by the European Commission for the treatment of advanced (unresectable or metastatic) melanoma in adults.
A new program from the Institute for Clinical and Economic Review will produce public reports that include a full analysis of the comparative effectiveness, the cost-effectiveness, and the potential budget impact of new drugs.
The study, published in the Annals of Internal Medicine, examined antibiotic prescribing pratices within the Department of Veterans Affairs.
The results will not wipe out a recent $2.37 billion settlement reached in about 9000 bladder cancer claims involving the drug.
The new law was part of a 21-bill package to fight one of the nation's highest rates of opioid and heroin abuse.
Researchers at UCLA have discovered that inhibiting SGLT2 in pancreatic and prostate adenocarcinomas can reduce cancer cell survival.